Medpace Holdings Inc (NASDAQ:MEDP) CEO August J. Troendle sold 47,106 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $123.99, for a total transaction of $5,840,672.94. Following the completion of the transaction, the chief executive officer now directly owns 616,643 shares of the company’s stock, valued at $76,457,565.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ:MEDP opened at $119.35 on Friday. Medpace Holdings Inc has a twelve month low of $58.72 and a twelve month high of $144.49. The company has a market cap of $4.23 billion, a price-to-earnings ratio of 39.31 and a beta of 1.22. The stock has a fifty day simple moving average of $96.91 and a 200-day simple moving average of $88.75. The company has a current ratio of 0.94, a quick ratio of 0.89 and a debt-to-equity ratio of 0.16.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 27th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.28. Medpace had a return on equity of 16.05% and a net margin of 12.11%. The business had revenue of $205.00 million during the quarter, compared to the consensus estimate of $181.17 million. During the same period last year, the company earned $0.81 earnings per share. The business’s revenue for the quarter was down 4.3% compared to the same quarter last year. As a group, equities research analysts predict that Medpace Holdings Inc will post 3.21 EPS for the current fiscal year.

A number of research analysts recently weighed in on MEDP shares. Credit Suisse Group raised their target price on shares of Medpace from $92.00 to $114.00 and gave the company an “outperform” rating in a report on Tuesday. SunTrust Banks raised their price target on Medpace from $95.00 to $124.00 and gave the stock a “hold” rating in a research report on Wednesday. Robert W. Baird upgraded Medpace from an “underperform” rating to a “neutral” rating and set a $83.00 price target for the company in a research report on Monday, June 8th. Zacks Investment Research upgraded Medpace from a “hold” rating to a “strong-buy” rating and set a $137.00 price target for the company in a research report on Saturday. Finally, Wolfe Research downgraded Medpace from an “outperform” rating to a “peer perform” rating and set a $91.00 price target for the company. in a research report on Wednesday, May 13th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $103.29.

Large investors have recently added to or reduced their stakes in the company. Fortis Advisors LLC bought a new stake in shares of Medpace during the first quarter worth $30,000. Private Capital Group LLC lifted its position in shares of Medpace by 162.4% during the first quarter. Private Capital Group LLC now owns 858 shares of the company’s stock worth $63,000 after purchasing an additional 531 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of Medpace during the first quarter worth $64,000. Sandy Spring Bank bought a new stake in shares of Medpace during the first quarter worth $65,000. Finally, Allred Capital Management LLC bought a new stake in shares of Medpace during the first quarter worth $87,000. Institutional investors and hedge funds own 79.83% of the company’s stock.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.